Latest Breaking News On - Robert hagan - Page 9 : vimarsana.com

 E-Mail IMAGE: Matthew Foster, MD, and his UNC Lineberger colleagues have used an experimental safety switch incorporated as part of a chimeric antigen receptor-modified T cell therapy (CAR-T) for an aggressive form. view more  Credit: UNC Lineberger Comprehensive Cancer Center CHAPEL HILL, North Carolina UNC Lineberger Comprehensive Cancer Center researchers have successfully used an experimental safety switch, incorporated as part of a chimeric antigen receptor T-cell (CAR-T) therapy, a type of immunotherapy, to reduce the severity of treatment side effects that sometimes occur. This advance was seen in a patient enrolled in a clinical trial using CAR-T to treat refractory acute B-cell leukemia. It demonstrates a proof-of-principle for possible expanded use of CAR-T immunotherapy paired with the safety switch.

Winnie lauNatalie groverRobert haganAnastasia ivanovaBrianne buchananMatthew fosterDaiichi sankyoKaitlin morrisonCatherine chengJames coghillSpencer laingAaron fosterPaul armisteadJohn westBarbara savoldoJonathan serody